使用心脏磁共振成像在肥厚型心肌病患者中筛查法布雷病
前瞻性队列纳入602例肥厚型心肌病表型患者,行心脏磁共振及基因检测诊断法布雷病,患病率1.8%(11例)。法布雷病组原生T1 mapping显著低于肥厚型心肌病组(1174.08±60.60 vs 1293.94±55.86,p<0.001);左心室基底段原生T1 mapping筛查性能最佳(截断值1216 ms,AUC 0.947,敏感度91%,特异度90%)。
要点
- 肥厚型心肌病表型患者中法布雷病患病率为1.8%(11例)。
- 法布雷病组原生T1 mapping显著低于肥厚型心肌病组。
- 左心室基底段原生T1 mapping截断值1216 ms,AUC 0.947,敏感度91%,特异度90%。
核心结论
- 原生T1 mapping是中国肥厚型心肌病表型人群中筛查法布雷病的最佳参数。
研究设计与样本
- 前瞻性队列,2012年4月至2022年12月纳入602例肥厚型心肌病表型患者,行心脏磁共振多参数成像及基因检测,法布雷病诊断依据基因检测和α-半乳糖苷酶A酶活性检测。
关键影像表现/征象
- 心脏功能、质量、室壁厚度及心肌应变在法布雷病与肥厚型心肌病组间无显著差异。
- 法布雷病组原生T1 mapping显著低于肥厚型心肌病组(1174.08±60.60 vs 1293.94±55.86,p<0.001)。
诊断标准与关键数值
- 左心室基底段原生T1 mapping筛查肥厚型心肌病表型中的法布雷病:截断值1216 ms,AUC 0.947,敏感度91%,特异度90%。
临床应用与阅片要点
- 原生T1 mapping是肥厚型心肌病表型人群中筛查法布雷病的最佳心脏磁共振参数。
- 作者认为原生T1 mapping为临床快速筛查法布雷病提供了有效方法,可能有助于识别患者以进行法布雷病早期治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Fabry disease (FD) usually mimics hypertrophic cardiomyopathy (HCM). Decreased native T1 mapping and a unique late gadolinium enhancement (LGE) pattern by cardiac magnetic resonance (CMR) imaging are specific imaging markers for FD.
PURPOSE: Explore the performance of multiparametric CMR imaging in screening for FD in patients with a HCM phenotype.
MATERIALS AND METHODS: A prospective cohort of 602 patients with a HCM phenotype was assessed from April 2012 to December 2022. Participants underwent CMR imaging and genetic testing. FD diagnosis was according to genetic testing and enzyme-activity test of α-galactosidase A. Multiparameter CMR imaging included cardiac function, native T1 mapping, extracellular volume (ECV), T2 mapping, LGE, and myocardial strains. Diagnostic performance of CMR parameters in identifying FD from HCM was done by analysis of receiver operating characteristic (ROC) curves.
RESULTS: FD prevalence was 1.8% (11 cases) in this cohort with HCM. Native T1 mapping was significantly lower in FD compared with HCM (FD vs. HCM: native T1 mapping: 1174.08 ± 60.60 vs. 1293.94 ± 55.86, p < 0.001). Ventricular function, mass, ventricular wall thickness, and strains did not show significant differences between the two groups. Binary logistic regression and analysis of ROC curves demonstrated myocardial native T1 mapping of the left ventricular basal slice had the best performance in screening for FD in patients with a HCM phenotype (cutoff: 1216 ms; AUC: 0.947; sensitivity: 91%; specificity: 90%).
CONCLUSION: Native T1 mapping is the best parameter for screening FD in a Chinese population with a HCM phenotype.
KEY POINTS: Question The prevalence of Fabry Disease (FD) in the study population is unknown and the efficacy of cardiac MRI (CMR) parameter screening for FD needs validating. Findings We report the prevalence of FD among a Chinese hypertrophic cardiomyopathy (HCM) cohort and found T1 mapping is the best CMR parameter for screening FD. Clinical relevance Native T1 mapping is the best CMR parameter for screening FD in the HCM cohort, providing an effective method for rapid screening of FD in clinic, which may help identify patients for early treatment of FD.
引用
- Li J, Pu L, Xu Z, et al. Screening for Fabry disease in patients with hypertrophic cardiomyopathy using cardiac magnetic resonance imaging. Eur Radiol. 2024. PMID: 39562366. doi:10.1007/s00330-024-11203-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。